Teleflex announced the U.S FDA has cleared the QuikClot Control+ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy. This allows clinicians to use the QuikClot Control+ Device to control all bleeding in cardiac surgical procedures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TFX:
- Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures
- TFX Earnings this Week: How Will it Perform?
- Teleflex price target raised to $315 from $305 at Stephens
- Teleflex to Acquire Palette Life Sciences
- Teleflex to acquire Palette Life Sciences for $600M upfront cash payment